Table 1.
Demographic and clinical features of patients with PD
| Clinical variables | European dataset | USA dataset | ||||||
| Non-carriers | GBAcarriersa | Severe mutation carriers | Mild mutation and risk variant carriers | Non-carriers | GBA carriersa | Severe mutation carriers | Mild mutation and risk variant carriers | |
| N (%) | 386 (87.9) | 53 (12.1) | 6 (1.4) | 45 (10.3) | 409 (91.9) | 36 (8.1) | 5 (1.1) | 29 (6.5) |
| Male, N (%) | 233 (60.3) | 34 (64.2) | 4 (66.7) | 28 (62.2) | 245 (60.5) | 28 (77.8) | 3 (60.0) | 25 (86.2) |
| Age at diagnosis | 71.1 (13.9) | 66.7 (14.2) | 63.0 (11.0) | 68.8 (13.6) | 70.0 (14.0) | 66.0 (10.0) | 66.0 (13.0) | 67.0 (9.0) |
| Positive family history, N (%) | 49 (12.7) | 7 (13.5) | 0 (0.0) | 7 (15.9) | 55 (13.6) | 4 (11.1) | 0 (0.0) | 4 (13.8) |
| Education, y | 11.1 (5.0) | 11.0 (5.5) | 11.7 (7.5) | 11.1 (5.0) | 14.0 (4.0) | 13.5 (3.9) | 13.6 (4.6) | 13.0 (4.0) |
| UPDRS/MDS-UPDRS III | 23.0 (16.5) | 21.0 (15.5) | 18.5 (18.5) | 21.0 (14.0) | 17.0 (14.0) | 20.7 (13.8) | 17.0 (17.3) | 20.4 (13.5) |
| Hoehn &Yahr | 2.0 (1.0) | 2.0 (1.0) | 2.0 (0.6) | 2.0 (1.0) | 2.0 (0.5) | 2.0 (1.5) | 2.0 (1.0) | 2.0 (1.5) |
| Duration of PD at baseline visit, y | 0.0 (0.1) | 0.0 (0.1) | 0.0 (0.04) | 0.0 (0.1) | 1.8 (2.4) | 1.2 (2.0) | 1.5 (2.7) | 1.2 (1.7) |
aGBA carriers include carriers of any GBA mutation, including those of unknown significance. Values presented as median (IQR) unless stated otherwise. MMSE, Mini-Mental State Examination; PD, Parkinson’s disease, UPDRS III, Unified Parkinson Disease Rating Scale Part III.